Sulfathiazole [2 (para-amino-benzene-sulfonamido) thiazole], the thiazole derivative of sulfanilamide, has been offered to the medical profession for clinical trial. Experimental work, both in vitro and in vivo, by Barlow and Homburger,1 McKee, Rake, Greep and van Dyke,2 Long and Bliss,3 and others has indicated that it probably is as effective in the treatment of pneumonia and certain other infections as sulfapyridine. Studies on the toxicity of the drug in animals by Long, Haviland and Edwards4 and van Dyke, Greep, Rake and McKee5 indicated that the drug could probably be safely used clinically under carefully controlled conditions. During the past two years numerous articles have appeared which would seem to indicate that sulfapyridine is an effective agent in the treatment of pneumonia. Among these publications was that of Wilson, Spreen, Cooper, Stevenson, Cullen and Mitchell6 at the Children's Hospital and in the pediatric wards of
WAGONER SC, HUNTING WF. SULFATHIAZOLE AND SULFAPYRIDINE: IN THE TREATMENT OF PNEUMONIA IN INFANCY AND CHILDHOOD. JAMA. 1941;116(4):267–270. doi:10.1001/jama.1941.02820040001001
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: